Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition

勃林格殷格翰动物健康公司宣布美国领导层换届

2021-01-14 18:19:31 BioSpace

本文共1602个字,阅读需5分钟

Boehringer Ingelheim Animal Health, a leading provider of medicine for pets, horses and livestock, announced today the appointment of Randolph Legg as its U.S. President. He succeeds Everett Hoekstra, who retired in December. Legg will remain head of the Company's U.S. commercial business while serving as president. "It's my honor to lead an organization dedicated to enhancing the well-being of people and animals," he said. Legg held various commercial leadership roles in Boehringer Ingelheim's Human Pharmaceutical division before moving to the company's Animal Health business in 2019 to lead the U.S. Pets Commercial team. He is based at the U.S. headquarters of Boehringer Ingelheim Animal Health in Duluth, Ga. Hoekstra retired after holding a variety of leadership roles at Boehringer Ingelheim. As president of Boehringer Ingelheim Animal Health in the U.S. for the last two years, he oversaw the final integration activities after Boehringer Ingelheim acquired Merial in 2017 to become the world's second-largest animal health company. Boehringer Ingelheim Animal Health also is transitioning a key global manufacturing role from its global headquarters in Ingelheim, Germany, to the United States. The company has named Dr. Helmut Finkler as Head of Regional Bio Manufacturing Americas & Global Manufacturing Science & Technology. He will oversee vaccine-production sites in the Americas, including in Athens, Ga., Gainesville, Ga., St. Joseph, Mo., and Guadalajara, Mexico. Finkler most recently served as Head of Global BIO Operations in Global Operations Animal Health. Legg and Finkler report to Jean-Michel Boers, President and CEO of Boehringer Ingelheim USA Corp. He oversees Boehringer Ingelheim's three business units in the United States: Human Pharmaceuticals, Animal Health and Bio-Pharmaceutical Contract Manufacturing. About Boehringer Ingelheim Animal Health The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both. Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases. Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.5 billion (4 billion euros) in 2019 and a presence in more than 150 countries. Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH. About Boehringer Ingelheim Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good. As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life. We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come. More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com. multimedia:http://www.prnewswire.com/news-releases/boehringer-ingelheim-animal-health-announces-us-leadership-transition-301207463.html
伯林格殷格翰动物保健公司是一家领先的宠物,马和家畜药物供应商,今天宣布任命伦道夫·莱格为其美国区总裁。他将接替去年12月退休的埃弗雷特•胡克斯特拉。 在担任总裁期间,莱格将继续负责公司的美国商业业务。 他说:“能领导一个致力于增进人类和动物福祉的组织是我的荣幸。” 莱格曾在勃林格殷格翰人类制药部门担任多项商业领导职务,之后于2019年跳槽至该公司动物健康业务,领导美国宠物商业团队。他在美国总部的勃林格殷格翰动物健康位于德卢斯,佐治亚州。 胡克斯特拉在勃林格殷格翰担任多种领导职务后退休。作为勃林格殷格翰动物保健公司美国区总裁,他在2017年收购Merial公司,成为全球第二大动物保健公司后,监督了最终的整合活动。 Boehringer Ingelheim Animal Health也正在将其关键的全球制造角色从位于德国Ingelheim的全球总部转移到美国。该公司任命赫尔穆特芬克勒博士为美洲地区生物制造和全球制造科学与技术的负责人。他将监督美洲的疫苗生产基地,包括美国的雅典,美国的盖恩斯维尔,美国的圣约瑟夫和墨西哥的瓜达拉哈拉。芬克勒最近担任全球动物健康运营部门的全球生物运营主管。 莱格和芬克勒向勃林格殷格翰美国公司总裁兼首席执行官Jean-Michel Boers汇报。他负责勃林格殷格翰在美国的三个业务部门:人类制药,动物保健和生物制药合同制造。 关于勃林格殷格翰动物健康 动物和人类的生活以深刻而复杂的方式相互联系。我们知道,当动物健康时,人类也更健康。在全球,我们的10,000名员工致力于通过创新提供价值,从而增进双方的福祉。 尊重动物,人类和环境是我们所做工作的核心。我们开发解决方案并提供服务,保护动物免受疾病和痛苦。我们支持我们的客户照顾他们的动物的健康,保护我们的社区免受威胁生命和社会的疾病。 勃林格殷格翰动物保健是全球第二大动物保健业务,2019年净销售额为45亿(40亿欧元),业务遍及150多个国家。 勃林格殷格翰动物保健公司在美国拥有大量的业务,在乔治亚州,密苏里州,爱荷华州,明尼苏达州,新泽西州和波多黎各等地拥有3100多名员工。欲了解更多信息,请访问www.boehringer-ingelheim.us,www.facebook.com/boehringerahus或www.twitter.com/boehringer_ah。 勃林格殷格翰简介 为人类和动物制造新的,更好的药物是我们工作的核心。我们的使命是创造改变生活的突破性疗法。自1885年成立以来,勃林格殷格翰一直是独立的家族企业。我们有自由追求我们的长远目标,展望未来,确定未来的卫生挑战,并针对那些我们可以尽最大努力的需要领域。 作为一家世界领先,以研究为动力的制药公司,超过51,000名员工每天通过创新为我们的三个业务领域创造价值:人类制药,动物健康和生物制药合同制造。 2019年,勃林格殷格翰实现了213亿(190亿欧元)的净销售额。我们在研发方面的重大投资超过39亿欧元(35亿欧元),推动创新,使下一代药品能够拯救生命,提高生活质量。 我们通过拥抱伙伴关系的力量和生命科学界专家的多样性,实现更多的科学机会。通过共同努力,我们将加速实现下一个医学突破,这一突破将改变患者现在和未来几代人的生活。 有关勃林格殷格翰公司的更多信息,请访问www.boehringer-ingelheim.com或查阅我们的年度报告:http://annualreport.boehringer-ingelheim.com。 多媒体:http://www.prnewswire.com/news-releases/boehringer-ingelheim-animal-health-announces-us-leadership-transition-301207463.html

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文